2026年11月2日星期一
M
Panorama Universal
Noticias globales
Nuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaAI dubbing to help Japanese companies expand global outreach— 日经 Nikkei AsiaIndonesia GDP, US midterm elections, Hong Kong financial summit— 日经 Nikkei AsiaPakistan refineries report 1,860% jump in profit amid war windfall— 日经 Nikkei AsiaAfter US midterms, democracy will face test of ability to self-correct— 日经 Nikkei AsiaThai reformists became too technocratic, party ex-leader Pita says— 日经 Nikkei AsiaJapan bamboo chopsticks catch on in South Korea— 日经 Nikkei AsiaOn India's east coast, tidepooling inspires marine conservation— 日经 Nikkei AsiaNuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaAI dubbing to help Japanese companies expand global outreach— 日经 Nikkei AsiaIndonesia GDP, US midterm elections, Hong Kong financial summit— 日经 Nikkei AsiaPakistan refineries report 1,860% jump in profit amid war windfall— 日经 Nikkei AsiaAfter US midterms, democracy will face test of ability to self-correct— 日经 Nikkei AsiaThai reformists became too technocratic, party ex-leader Pita says— 日经 Nikkei AsiaJapan bamboo chopsticks catch on in South Korea— 日经 Nikkei AsiaOn India's east coast, tidepooling inspires marine conservation— 日经 Nikkei Asia

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

Fuente Nature 医学研究Hace 4 días
Resumen del contenido

Este sitio solo proporciona títulos e índices de resúmenes; el contenido completo y los derechos de autor pertenecen al publicador original. Haga clic en el enlace original para leerlo.

Ir al texto original
Canal al que pertenece
Salud
Región a la que pertenece
Perspectiva global
Idioma original
English
Número de entrada
health-a97f47b5

Comments 0 comments

No comments yet. Be the first.

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial · Panorama Universal